Tegumentary leishmaniasis (TL) is a tropical parasitic disease with approximately one million estimated cases annually ([@B1]). The most affected areas in the world are the Americas, the Mediterranean basin and western Asia, from the Middle East to Central Asia. In the New World, TL is caused by *Leishmania (Viannia) braziliensis*. Brazil is among the countries with the highest estimated number of cases ([@B1]). In Brazil, the state of Mato Grosso (MT) comprises a large area of the country and cutaneous leishmaniasis is endemic in this state. The Tropical Infectious Diseases Unit of the Mato Grosso Federal University Hospital has been serving as a reference centre for the diagnosis and treatment of cutaneous leishmaniasis since the 1990s.

Globally, antimony compounds such as sodium stibogluconate and meglumine antimoniate are the first choices for the treatment of TL. This group of drugs has severe side effects that mainly affect cardiac, liver, muscle and metabolic functions. In 1966, herpes zoster was, for the first time, described in association with a treatment involving antimony compounds ([@B2]). Herpes zoster, commonly known as "shingles*",*is a reactivation of the varicella zoster virus after becoming latent after a primary infection. The reactivation occurs mainly among the elderly and in immunosuppressed patients, including those with human immunodeficiency virus (HIV) infection and those using immunosuppressive drugs ([@B7]).

Since the first report of herpes zoster complicating antimony treatment for leishmaniasis ([@B2]), new cases have been reported in Kenya, Belize and Peru and in American soldiers serving in the Middle East. Most of the reports involved isolated cases, with the largest series describing five cases ([@B8]). All of these cases were associated with the use of sodium stibogluconate ([@B5], [@B6], [@B11], [@B12], [@B8]).

The main objective of this paper is to describe the incidence of herpes zoster reactivation at a specialised clinic in Brazil.

A review of the medical records of patients treated for leishmaniasis between August 1994-May 2008 was performed at the Infectious Diseases Clinic of the Julio Müller University Hospital (Cuiaba, MT). The records were reviewed to obtain clinical and demographic data, including treatment options, associated illness, HIV infection and other causes of immunosuppression, and to evaluate the incidence of herpes zoster during antimony treatment or within a 90-day observation period after the completion of therapy. Complete data were available for 16 patients.

The Infectious Diseases Clinic uses antimony according to the doses and schedules recommended by the Brazilian Ministry of Health. For meglumine antimoniate, doses of 10-15 mg/kg/day for 20 days are recommended for cutaneous leishmaniasis and 20 mg/kg/day for 30 days is recommended for mucosal leishmaniasis ([@B9]). For sodium stibogluconate, doses of 10 mg/kg/day for 20 days are recommended for cutaneous leishmaniasis and 20 mg/kg/day for 30 days is recommended for mucosal leishmaniasis. Since 1997, the only antimony compound used in Brazil has been meglumine antimoniate ([@B9]).

The data were analysed using Epi Info v.6.04d (Centers for Disease Control, USA) and STATA 5.0 (Stata Corp, USA).

The study was approved by the Research Ethical Committee of Julio Müller University Hospital (099-CEP-HUJM/2003). All data analysed in this study were anonymised and written consent was not required because the data were obtained from medical records, without any direct contact with patients.

From 1994-2008, 2,137 cases of TL were treated and 16 cases of herpes zoster were identified in patients treated for cutaneous leishmaniasis with either meglumine antimoniate or sodium stibogluconate. In this case series, the median time to the appearance of shingles was 22.1 days (range, 8-36 days) after the beginning of antimony therapy. The cumulative probability of herpes zoster occurring after the start of antimony therapy is shown in [Figure](#f01){ref-type="fig"}.

Cumulative probability of the development of herpes zoster during treatment with antimony compounds.

Most patients were young males living in rural areas, similar to most patients in Brazil ([@B10]). Four cases were associated with the use of sodium stibogluconate and 12 were associated with the use of meglumine antimoniate. At the time of the writing of this report, there were no other references to herpes zoster during or after use of meglumine antimoniate. The time between the start of antimony therapy and the appearance of herpes zoster, as well as the dose of elementary antimony received, were similar between patients who took either antimony drug ([Table](#t01){ref-type="table"}). Of the patients developing herpes zoster, 15 did not show any obvious cause of immunosuppression and only one was HIV positive. At the time of the appearance of herpes zoster, the HIV-positive patient had 93 CD4 T lymphocytes per mm^3^.

TABLECharacteristics of patients with herpes zoster infection during the treatment of cutaneous leishmaniasis with antimony compoundsCharacteristicsn (%)pSex   Male15 (93.8)- Female1 (6.3)-Age (years) \[median (range)\]53.3 (22-81)-Drug   Meglumine antimoniate12 (75)- Sodium stibogluconate4 (25)-Human immunodeficiency virus infection1 (6.3)-Time of appearance (days) \[median (range)\]22.1 (8-36)-Meglumine antimoniate \[median (range)\]27.0 (11-36)0.11Sodium stibogluconate \[median (range)\]16.5 (8-20)-

The mechanism of action of antimony compounds is still not completely understood. This group of drugs causes disruptions in cell division and/or cell signalling processes ([@B12], [@B13]) and may increase or decrease the number of CD4^+^ and CD8^+^ T cell clones ([@B12]). Because there are few reports of herpes zoster infection during the use of antimony compounds in the treatment of TL, the association of these cases with a decrease in T cell counts or with transient immunosuppression induced by antimony treatment has not been established ([@B13]).

Between 1998-2001, there were 6,247 incident cases of herpes zoster identified among active-duty United States of America (USA) service members, yielding a crude rate of 0.95 per 1,000 persons per month ([@B3]). Overall, the incidence of herpes zoster in the USA is 3.2 cases per 1,000 persons per year, reaching 10 cases per 1,000 persons per year for patients over 75 years of age and 14.5 cases per 1,000 persons per year for patients being treated with immunosuppressive drugs ([@B4]). Considering all TL patients treated at the Infectious Diseases Clinic during the study period and the recommended observation period of three months after drug interruption, the incidence of herpes zoster infection was approximately 2.5 cases per 1,000 persons per month (or 30 per 1,000 persons per year). However, for certain patients, the observation period was less than three months because they lived in rural areas, far from healthcare facilities. Thus, the actual incidence of herpes zoster infection among these patients could have been higher than that reported here. The incidence rate in this group of patients was high, especially because most of the patients were young adults. This fact reinforces the impression that there is a causal relationship between the use of antimony compounds for the treatment of TL and herpes zoster infection. Further research is necessary to improve our understanding of the mechanisms of the immune system disruption associated with these drugs, which results in the reactivation of latent varicella zoster infections.

In conclusion, this report describes more cases than the number of all published cases of herpes zoster infection that developed during the treatment of cutaneous leishmaniasis with antimony compounds. There are no previous reports of an association between herpes zoster and the use of meglumine antimoniate in the medical literature. The treatment of cutaneous leishmaniasis with antimony compounds appears to be a risk factor for reactivation of herpes zoster infection.
